Asthika Goonewardene
Stock Analyst at Truist Securities
(1.19)
# 3,424
Out of 4,827 analysts
92
Total ratings
32.93%
Success rate
-15.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.23 | +713.01% | 4 | Apr 1, 2025 | |
| GMAB Genmab | Maintains: Buy | $50 → $45 | $20.60 | +118.45% | 14 | Mar 11, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $15 | $3.13 | +379.23% | 6 | Mar 3, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $7 | $4.06 | +72.63% | 3 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Buy | $42 → $43 | $36.81 | +16.82% | 8 | Jan 27, 2025 | |
| IGMS IGM Biosciences | Maintains: Hold | $12 → $2 | $1.14 | +75.44% | 8 | Jan 10, 2025 | |
| BNTX BioNTech SE | Initiates: Buy | $172 | $92.80 | +85.34% | 1 | Jan 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $35 | $24.25 | +44.33% | 1 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $53.07 | +156.27% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $83 → $97 | $98.90 | -1.92% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $0.99 | +1,409.97% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 → $14 | $1.20 | +1,066.67% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $7.92 | +455.91% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $31.42 | +180.08% | 1 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $39.43 | +123.18% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.25 | +221.29% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $0.76 | +2,400.00% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.32 | +2,673.50% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.61 | +2,384.47% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.49 | +5,405.71% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $12.36 | +870.87% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.67 | +3,492.81% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $0.38 | +3,849.45% | 4 | Aug 23, 2022 |
Autolus Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.23
Upside: +713.01%
Genmab
Mar 11, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $20.60
Upside: +118.45%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.13
Upside: +379.23%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $7
Current: $4.06
Upside: +72.63%
Exelixis
Jan 27, 2025
Maintains: Buy
Price Target: $42 → $43
Current: $36.81
Upside: +16.82%
IGM Biosciences
Jan 10, 2025
Maintains: Hold
Price Target: $12 → $2
Current: $1.14
Upside: +75.44%
BioNTech SE
Jan 10, 2025
Initiates: Buy
Price Target: $172
Current: $92.80
Upside: +85.34%
Summit Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $24.25
Upside: +44.33%
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $53.07
Upside: +156.27%
Gilead Sciences
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $98.90
Upside: -1.92%
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $0.99
Upside: +1,409.97%
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $1.20
Upside: +1,066.67%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $7.92
Upside: +455.91%
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $31.42
Upside: +180.08%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $39.43
Upside: +123.18%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.25
Upside: +221.29%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $0.76
Upside: +2,400.00%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $0.32
Upside: +2,673.50%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $1.61
Upside: +2,384.47%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.49
Upside: +5,405.71%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $12.36
Upside: +870.87%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.67
Upside: +3,492.81%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $0.38
Upside: +3,849.45%